This is similar to previous studies that reported the prevalence of multi-hit PIK3CA mutations across tumor types.18,35 In a highly prevalent disease such as CRC a 1.7% prevalence is a clinically meaningful subset of patients who may have enhanced sensitivity to PI3K inhibitors via increased PI3K⍺ signaling, leading to improved treatment responses.18,35. The gene discussed is PIK3CG; the disease is colorectal carcinoma.